Singapore markets closed

TELA Bio, Inc. (TELA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.77+0.83 (+16.80%)
At close: 04:00PM EDT
5.80 +0.03 (+0.51%)
After hours: 04:26PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.94
Open5.43
Bid5.70 x 100
Ask5.78 x 100
Day's range5.43 - 6.00
52-week range4.24 - 11.26
Volume404,203
Avg. volume154,072
Market cap142.253M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-2.04
Earnings date07 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.60
  • GlobeNewswire

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock unit

  • GuruFocus.com

    TELA Bio Inc (TELA) Reports Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Continued Growth

    TELA Bio Inc (TELA) released its 8-K filing on May 9, 2024, revealing a significant revenue increase and strategic expansions

  • GlobeNewswire

    TELA Bio Reports First Quarter 2024 Financial Results

    MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand fo